Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts
Fibroblast growth factor 23 (FGF23) is the cornerstone of phosphate / calcium / vitamin D
 metabolism: it is synthesized mainly by osteocytes and acts as a Phosphating agent, inhibitor
 of dihydroxyvitamin D, and inhibitor of synthesis and secretion of Parathyroid hormone (PTH)
 in most tissues.

 The specific role of FGF23 on bone has yet to be demonstrated. In some diseases such as
 hypophosphatemic rickets (HR), the direct role of FGF23 on bone has not yet been studied to
 our knowledge, whereas these genetic hypophosphatemias are secondary to overexpression of
 FGF23, whether an activating mutation of FGF23 or inhibitory mutations of its inhibitors
 (Dentin matrix acidic phosphoprotein 1 (DMP1) and Phosphate-regulating neutral endopeptidase,
 X-linked (PHEX)). However, patients with X-linked hypophosphatemic rickets (XLH) have higher
 circulating FGF23 levels than healthy controls and these levels are higher in treated
 patients.

 Management of XLH consists primarily of correcting the native vitamin D defect by prescribing
 active vitamin D analogs as well as phosphate supplementation to improve bone mineralization
 and decrease dental complications, growth, and bone deformities. Recently, a new therapeutic
 option has been developed for XLH, burosumab, a human monoclonal antibody that binds and
 inhibits FGF23 activity. The use of burosumab is currently authorized in France in some
 pediatric patients with severe forms of XLH.

 Independently of the indirect bone effects of phosphate correction and vitamin D levels, the
 direct role of burosumab on bone cells has never been studied. The objective of this project
 is to study the osteoclastic biology of patients with HR compared to control patients, and to
 evaluate the direct impact of the treatments used in this pathology on human osteoclasts.
hypophosphatemic rickets patients:

 Inclusion Criteria:

 -  children from 2 yars-old to 18 years old and adults

 -  patients with HR followed in the center of calcium and phosphorus metabolism rare
 diseases in Lyon-

 -  Patients and parent / holder of parental authority who have been informed of the study
 and do not object to participate

 Exclusion Criteria:

 -  Patient being treated with oral corticosteroid or having received more than 3 months
 of corticosteroid treatment before surgery.

 -  Patients under tutorship or curatorship

 -  Pregnant and / or breastfeeding woman

 -  Patient deprived of liberty

 Controls patients:

 Inclusion Criteria:

 -  children from 2 years-old to 18 years old and adults

 -  patients with normal renal function (Schwartz glomerular filtration rate (GFR) >90
 ml/min/1.73m²)

 -  Patients and parent / holder of parental authority who have been informed of the study
 and do not object to participate

 Exclusion Criteria:

 -  Patient being treated with oral corticosteroid or having received more than 3 months
 of corticosteroid treatment before surgery.

 -  Patients under tutorship or curatorship

 -  Pregnant and / or breastfeeding woman

 -  Patient deprived of liberty

 -  Patient treated with immunosuppressive drugs

 -  Patient with inflammatory disease